Ειδήσεις: OCUGEN | PXAI

Version	Description	Date
8.42	[ADDED SOURCE REGISTRY LIST VIEW]	04/03/2026 16:19
8.41	[LOCALIZED INDEX.PHP MENU AND MODALS TO US ENGLISH]	04/03/2026 16:11
8.40	[TRANSLATED FRONTEND TO US ENGLISH]	04/03/2026 16:10
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:50
8.41	[RESTORED DETAILED SOURCES VIEW (ARTICLES + EVENTS) IN US ENGLISH]	04/03/2026 15:46
8.40	[REVERTED TO STANDARD TABLE LAYOUT (US ENGLISH)]	04/03/2026 15:40
8.39	[FIXED DB CONNECTION SCOPE IN SOURCES LOGIC]	04/03/2026 15:38
8.38	[TRANSLATED SOURCES VIEW TO US ENGLISH]	04/03/2026 15:01
8.37	[FULL FRONTEND TRANSLATION (MENU, FEED, COMMENTS, TTS) TO US ENGLISH.]	04/03/2026 14:58
8.67	[MANUAL OVERRIDE OF GREEK MENU ITEMS]	04/03/2026 13:36
8.66	[NGINX OPTIMIZED MENU FIX]	04/03/2026 13:33
8.65	[FIXED GREEK MENU ITEMS]	04/03/2026 13:32
8.60	[MENU & UI LOCALIZATION TO US ENGLISH]	04/03/2026 13:30
8.50	[FULL TRANSLATION TO US ENGLISH]	04/03/2026 13:27
9.75	[INJECTED EVENT FUSION_SUMMARY INTO FEED LOOPS TO DISPLAY AI TAGS CORRECTLY]	26/02/2026 14:44

31/03 08:32 defenseworld.net

Aprea Therapeutics (NASDAQ:APRE) versus Ocugen (NASDAQ:OCGN) Head-To-Head Comparison

small‑cap biotech Aprea Therapeutics Ocugen analyst ratings price target upside potential

27/03 07:54 defenseworld.net

HC Wainwright Forecasts Strong Price Appreciation for Ocugen (NASDAQ:OCGN) Stock

Ocugen HC Wainwright price target buy rating market coverage Canaccord Genuity

26/03 08:04 defenseworld.net

Ocugen Shares Phase II OCU410 Data Showing 31% Slower GA Lesion Growth at 12 Months

Ocugen OCU410 geographic atrophy dry age‑related macular degeneration gene therapy Phase II

24/03 14:51 investing.com

Ocugen stock falls 5% despite positive gene therapy trial data

Ocugen gene therapy biotech stock decline clinical trial investor sentiment

13/03 08:36 defenseworld.net

Oppenheimer Begins Coverage on Ocugen (NASDAQ:OCGN)

Oppenheimer Ocugen outperform price target analyst ratings 327% upside

13/03 08:36 defenseworld.net

Oppenheimer Begins Coverage on Ocugen (NASDAQ:OCGN)

Oppenheimer Ocugen outperform price target analyst ratings 327% upside

Loading...